XML 94 R54.htm IDEA: XBRL DOCUMENT v3.20.1
License agreements - Agenus (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 14, 2017
USD ($)
$ / shares
Feb. 01, 2017
USD ($)
$ / shares
shares
Nov. 30, 2015
item
Jan. 31, 2015
item
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2018
USD ($)
Feb. 28, 2017
USD ($)
License agreements                      
Long term investments         $ 180,993     $ 133,657 [1]      
Research and development expense         1,085,287 $ 270,545          
Unrealized gain (loss) on long term investments         (48,132) 20,989          
Current assets         1,716,169     2,481,488 [1]      
Current liabilities         $ 503,412     513,340 [1]      
Agenus                      
License agreements                      
Number of program targets | item     3 4              
Royalty payments on future global net sales (as a percent)         15.00%            
Agenus | Development, Regulatory and Commercialization Milestones | Minimum                      
License agreements                      
Royalty payments on future global net sales (as a percent)         6.00%            
Agenus | Development, Regulatory and Commercialization Milestones | Maximum                      
License agreements                      
Royalty payments on future global net sales (as a percent)         12.00%            
Agenus                      
License agreements                      
Long term investments         $ 43,500     72,300      
Research and development expense         $ 100 10,200          
Ownership percentage (as a percent)         11.00%            
Unrealized gain (loss) on long term investments         $ (28,800) $ 10,500          
Total revenues               150,000      
Net income (loss)               111,600      
Agenus | Accrued and other liabilities                      
License agreements                      
Accrued and other liabilities         $ 1,400     $ 1,600      
Agenus | Development, Regulatory and Commercialization Milestones | Maximum                      
License agreements                      
Additional milestone payments under the license agreement                     $ 510,000
Agenus | Development Milestones                      
License agreements                      
Upfront payment under license agreement                 $ 20,000    
Agenus | Development Milestones | LAG-3 program                      
License agreements                      
Additional milestone payments under the license agreement                   $ 5,000  
Agenus | Development Milestones | TIM-3 program                      
License agreements                      
Additional milestone payments under the license agreement                   $ 5,000  
Agenus | Stock purchase agreement                      
License agreements                      
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares   10.0                  
Purchase price of common stock   $ 60,000                  
Per share price | $ / shares $ 4.40 $ 6.00                  
Discount for lack of marketability $ 4,500                    
Fair value of shares on the issuance date 39,500                    
Total consideration paid $ 60,000                    
Long term investments             $ 39,500        
Research and development expense             $ 20,500        
[1] The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date.